Infectious Disease

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

Researchers identify certain predictive factors that impact the prognosis of patients with myasthenia gravis and COVID-19 infection.

A new study highlights risk factors for hospitalization and severe illness among adults with respiratory syncytial virus (RSV) receiving care through the emergency department.

Survey reveals gaps in vaccination intentions for flu, COVID-19, respiratory syncytial virus, and pneumococcal disease.

Ziresovir reduces respiratory syncytial virus (RSV) symptoms and viral load in infants, offering hope for an effective treatment.

More than half of healthy term infants born in the United States are infected with respiratory syncytial virus (RSV) during their first year of life, with significant hospitalization and illness rates observed.

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, hospitalizations, lost quality of life, and deaths, according to one study.

The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.

A new survey highlights lack of awareness about respiratory syncytial virus (RSV) among older adults, posing increased health risks for those with chronic conditions.

Infectious diseases were the leading causes of death on the first Labor Day, just ahead of a major epidemiological shift that brought both vaccines to fight these deadly ailments but also the rise of cigarette smoking.

An 18% reduction in acute care encounters for respiratory tract infections among infants 8 weeks or younger was identified following the implementation of New York's paid family leave policy.

A recent study estimates the prevalence of primary care and emergency department visits by young children to treat respiratory syncytial virus (RSV), finding that the rates vary widely by country.

Spotty vaccine supplies have consumers searching for protection as the FDA prepares to approve updated COVID-19 shots.

The current outbreak stems from the clade I strain of mpox, different from the clade II strain that caused the 2022 global health emergency.

CDC data from 2021 show the lifetime cost of treating syphilis to be $1190.

The respiratory syncytial virus (RSV) vaccine shows strong immunogenicity and safety in immunocompromised adults, study finds.

CDC’s Advisory Committee on Immunization Practices (ACIP) revises respiratory syncytial virus (RSV) vaccination guidelines to prioritize older adults and those at higher risk of severe disease.

In part 1 of this interview, Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), explained the research she presented at the 25th International AIDS Conference and the disparities migrant workers continue to encounter in HIV care.

New research highlights the increased risk of severe COVID-19 in individuals previously infected with respiratory syncytial virus (RSV).

We spoke with Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), who advocates at regional and global levels for policy reform of discriminatory practices that put migrant workers at risk of HIV and AIDS.

This research presented at AIDS 2024 shows that cognitive behavioral therapy (CBT) groups help to fill an unmet need among older persons living with HIV: to overcome the age-related health disparities this group experiences from being in long-term care and improve their health outcomes.

Researchers estimate the financial impact of respiratory syncytial virus (RSV) in cardiorespiratory hospitalizations using MarketScan data and CDC viral positivity rates.

Efforts to regulate social media for youth face resistance; MK-1654 meets key goals in mid-to-late stage trial; active drug shortages remain above 300 for sixth consecutive quarter.

Despite rising trends in respiratory syncytial virus (RSV) testing, more outpatient testing is needed for accurate RSV surveillance.

New rules aim to curb insurance brokers and protect consumers; data highlights surge in post-pandemic hospital-onset infections; President Biden’s decision to step down highlights Harris’ stance on health care reform and equity.

The effectiveness of nirsevimab therapy shows promise against respiratory syncytial virus (RSV)–associated bronchiolitis in a real-world setting.

Over the course of the pandemic, the risk of developing long COVID after a COVID-19 infection decreased, largely due to vaccination.

No increased risks of preterm birth or perinatal outcomes were identified with maternal vaccination status, according to one study.